Business Context and Reporting Period
This Form 8-K was filed by Dare Bioscience, Inc. on July 18, 2024, with the earliest event reported on the same date. The filing primarily addresses the company's regulatory status with The Nasdaq Capital Market and provides updates on its clinical development pipeline.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and operational milestones rather than financial performance data.
Material Changes
- Nasdaq Compliance: The company regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the $1.00 per share minimum bid price requirement. This followed a temporary exception granted by the Hearings Panel, during which the stock closed at $1.00 or greater for ten consecutive trading sessions prior to July 16, 2024.
- Regulatory Status: The matter regarding the minimum bid price is now officially closed as of July 18, 2024.
Outlook, Management Commentary, and Risks
Management continues to advance Phase 3 pivotal studies for Sildenafil Cream, 3.6%, intended for the treatment of female sexual arousal disorder, a condition with no current FDA-approved treatments. The company is awaiting further feedback from the FDA on:
- Proposed primary and secondary patient-reported outcome endpoints.
- Data requirements for a New Drug Application (NDA) submission to qualify ingredients other than sildenafil for vaginal administration.
- Clarification on the required safety database size and duration of exposure for NDA submission.
Risks: The company's progress remains contingent on FDA feedback and the successful execution of its Phase 3 studies.
Key Facts for Investor Verification
- Confirm the current trading price of DARE stock to ensure continued compliance with Nasdaq listing rules.
- Monitor upcoming FDA communications regarding the Phase 3 study endpoints and NDA data requirements for Sildenafil Cream.
- Review the press release (Exhibit 99.1) referenced in the filing for additional details on the compliance restoration.